Sino Biopharmaceutical Limited · Healthcare
$4.66
-53.0%
Jun 17, 2026
C
MarginalGraded against 1177's own history at this drawdown — not the market's.
What it means: 1177's own history does not strongly favor buying at this level yet.
What to do: Consider watching and waiting for a deeper dip or a higher grade.
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection
Three plain-English paragraphs — current state, historical base rate, and interpretation — so you walk away with context, not a dashboard.
In plain terms: 1177 is 53% below its highest-ever price. Dipsern checks every past time it was this far down and grades how the next 90 days usually went.
As of the latest market close, Sino Biopharmaceutical (1177) is trading in a severe drawdown, 53.0% below its all-time high at $4.66. Severe drawdowns separate structurally sound assets from the ones that don't recover. The historical data below shows what 1177 did after similar episodes.
1177 reaches this drawdown band repeatedly in its history (101 observations), which is a meaningful sample for the segmentation engine to compute a stable median forward return. The engine uses a rolling 90-day window and gives more weight to recent years — this lets the signal adapt to regime changes (e.g., post-COVID volatility) without losing the long-run base rate.
Drawdown-based signals work across asset classes but the magnitude of meaningful moves varies. Dipsern computes the segmentation per-asset so the bands are calibrated to 1177's own volatility history. At this depth, focus on prediction error and sample size before median return. A high historical median return at -40% means nothing if the prediction error was also 30%.
Five tickers closest to 1177's distance from all-time high. Same category, one tap away.
Dipsern segments the full drawdown range into 20 equal-width bands. The table shows the number of confirmed historical observations in each band for 1177. Median forward returns, win rates, and prediction errors are available in the full analysis.
We segment 40+ years of 1177's price history into 20 equal-width drawdown bands and compute forward median returns, win rates, and prediction error per band. No look-ahead bias. Pure NumPy. Open math, gated numbers.
Years of history
40+
Drawdown bands
20
Look-ahead bias
None
Data sources
4
See the Dipsern grade, median returns, win rates, prediction accuracy, 8 interactive charts, historical price paths, and a plain-English verdict for 1177.
Dipsern is research and a second opinion — not a broker. You'd buy 1177 at your own broker.
Analyze 1177 FreeNo credit card required · 5 free analyses per month
Signal computed Jun 17, 2026 using default parameters (90-day return period, 20 segments, 0.95 decay). Data sourced from Yahoo Finance, Binance, CoinGecko, and Steam Market.